Johnson & Johnson Booster Shot Said to be 94% Effective

Sep 21, 2021 By MarketDepth

Biotechnology Healthcare


Johnson & Johnson (NYSE: JNJ) announced Tuesday that its Covid-19 booster shot was 94% effective if administered two months after the initial dose within the United States. According to the company, the second J&J dose increases antibody levels four to six times in comparison to one shot alone.

“Our large real-world-evidence and Phase 3 studies confirm that the single-shot Johnson & Johnson vaccine provides strong and long-lasting protection against COVID-19-related hospitalizations.”

Dr. Mathai Mammen, global head of Janssen Research & Development

“Our single-shot vaccine generates strong immune responses and long-lasting immune memory. And, when a booster of the Johnson & Johnson COVID-19 vaccine is given, the strength of protection against COVID-19 further increases.”

Booster Effective

The multinational corporation revealed that if the J&J booster was given six months from the first dose, the shot was even more effective against Covid. Apparently, the booster would then generate antibodies twelvefold higher, four weeks after the booster, with no regards to the person’s age.

Side Effects Similar to First Dose

According to the company, the booster shot was well tolerated and had side effects consistent with the first dose.

“We now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly.”

J&J chief scientific officer Dr. Paul Stoffels

U.S. Health officials have said that they require more data regarding the company’s vaccine before authorizing the booster shots.